These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27749322)

  • 21. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
    Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
    J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer.
    Van der Auwera I; Peeters D; Benoy IH; Elst HJ; Van Laere SJ; Prové A; Maes H; Huget P; van Dam P; Vermeulen PB; Dirix LY
    Br J Cancer; 2010 Jan; 102(2):276-84. PubMed ID: 19953098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer.
    Zavridou M; Smilkou S; Tserpeli V; Sfika A; Bournakis E; Strati A; Lianidou E
    Clin Chem; 2022 Oct; 68(10):1323-1335. PubMed ID: 36093578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies.
    Ma Y; Luk A; Young FP; Lynch D; Chua W; Balakrishnar B; de Souza P; Becker TM
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27527157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
    Goldkorn A; Ely B; Tangen CM; Tai YC; Xu T; Li H; Twardowski P; Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Vogelzang NJ; Thompson IM; Cote RJ; Quinn DI
    Int J Cancer; 2015 Apr; 136(8):1856-62. PubMed ID: 25219358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.
    Zapatero A; Gómez-Caamaño A; Cabeza Rodriguez MÁ; Muinelo-Romay L; Martin de Vidales C; Abalo A; Calvo Crespo P; Leon Mateos L; Olivier C; Vega Piris LV
    Radiat Oncol; 2020 Jun; 15(1):137. PubMed ID: 32487218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
    Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.
    Todenhöfer T; Hennenlotter J; Feyerabend S; Aufderklamm S; Mischinger J; Kühs U; Gerber V; Fetisch J; Schilling D; Hauch S; Stenzl A; Schwentner C
    Anticancer Res; 2012 Aug; 32(8):3507-13. PubMed ID: 22843938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.
    Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES
    Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
    Goldkorn A; Tangen C; Plets M; Morrison GJ; Cunha A; Xu T; Pinski JK; Ingles SA; Triche T; Harzstark AL; Kohli M; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Vogelzang NJ; Thompson IM; Agarwal N
    Clin Cancer Res; 2021 Apr; 27(7):1967-1973. PubMed ID: 33500355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
    Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
    Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
    Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Lozano JJ; Jiménez N; García-Recio S; Erill N; Gaba L; Tagliapietra A; Ortega V; Carrera G; Colomer A; Gascón P; Mellado B
    Oncotarget; 2015 Apr; 6(12):10604-16. PubMed ID: 25871394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
    Zhang T; Armstrong AJ
    Curr Oncol Rep; 2016 Jan; 18(1):3. PubMed ID: 26700506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).
    Andree KC; Mentink A; Zeune LL; Terstappen LWMM; Stoecklein NH; Neves RP; Driemel C; Lampignano R; Yang L; Neubauer H; Fehm T; Fischer JC; Rossi E; Manicone M; Basso U; Marson P; Zamarchi R; Loriot Y; Lapierre V; Faugeroux V; Oulhen M; Farace F; Fowler G; Sousa Fontes M; Ebbs B; Lambros M; Crespo M; Flohr P; de Bono JS
    Int J Cancer; 2018 Nov; 143(10):2584-2591. PubMed ID: 30006930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes.
    Nimir M; Ma Y; Jeffreys SA; Opperman T; Young F; Khan T; Ding P; Chua W; Balakrishnar B; Cooper A; De Souza P; Becker TM
    Cells; 2019 Jul; 8(7):. PubMed ID: 31288377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
    Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
    Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.